

March 15, 2022



Sapience Therapeutics to Participate at SVB Leerink Biopharma Private Company Connect

HARRISON, N.Y., March 15, 2022 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of small protein therapeutics to address difficult-to-treat cancers, announced today that management will participate in one-on-one meetings with investors at the SVB Leerink Biopharma Private Company Connect event, being held virtually March 29-31, 2022.

About Sapience Therapeutics

Sapience Therapeutics, Inc. is a privately held, clinical stage biotechnology company focused on discovering and developing small protein therapeutics for major unmet medical needs, particularly high mortality cancers. Sapience's approach holds potential to target intracellular interactions that are traditionally considered "undruggable targets". Its lead program, ST101, is a small protein antagonist of C/EBP β that has demonstrated clinical proof-of-concept in Phase 1 with a confirmed partial response (PR). ST101 is currently being evaluated in the Phase 2 portion of an ongoing Phase 1-2 clinical study with potential applications in various solid tumors and hematologic malignancies. For more information on Sapience Therapeutics, please visit www.sapiencetherapeutics.com and engage with us on [LinkedIn](#).

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements. Any statements herein other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties (including with respect to Sapience's preclinical and clinical development programs). These forward-looking statements are based on management's current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. Forward-looking statements speak only as of the date of this press release. Sapience does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise, except as required by law.

Contacts

Sapience Therapeutics, Inc.
Barry Kappel, Ph.D., M.B.A.
President and Chief Executive Officer
info@sapiencetherapeutics.com

Media and Investor Contact:

Amy Conrad

Juniper Point

(858) 366-3243

amy@juniper-point.com

🔗 View original content: <https://www.prnewswire.com/news-releases/sapience-therapeutics-to-participate-at-svb-leerink-biopharma-private-company-connect-301502283.html>

SOURCE Sapience Therapeutics, Inc.